Study to Evaluate the Safety & Tolerability of Treatment With Atogepant 60

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06047457` - A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults	Phase 3
Completed	`NCT02569853` - DFN-11 Injection in Episodic Migraine With or Without Aura	Phase 3
Completed	`NCT00719134` - The Effects of Expectation and Knowledge on Rizatriptan and Placebo Treatment of Acute Migraine Headache	Phase 4
Terminated	`NCT04936061` - Transnasal Cooling for Migraine	N/A
Recruiting	`NCT05042037` - Probiotics as Adjunctive Migraine Prophylaxis	N/A
Recruiting	`NCT05281770` - Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study
Recruiting	`NCT04628429` - CGRP Inhibition, Autonomic Function, and Migraine
Active, not recruiting	`NCT05028569` - Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine	Phase 3
Withdrawn	`NCT01257893` - Aspirin Resistance in Women With Migraine	N/A
Recruiting	`NCT06051604` - Mi-Helper Transnasal Cooling for Acute Treatment of Migraine	N/A
Completed	`NCT03132233` - Energy for the Brain	N/A
Completed	`NCT03939312` - Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine	Phase 3
Completed	`NCT03927144` - Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients	Phase 4
Recruiting	`NCT06248671` - Prophylactic Treatment With Atorvastatin for Episodic Migraine.	Phase 2
Recruiting	`NCT05711394` - A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine	Phase 3
Recruiting	`NCT05449145` - The Effects of Vitamin D Plus Omega-3 Polyunsaturated Fatty Acids in Patients With Episodic Migraine	N/A
Completed	`NCT04031781` - The Role of Left Prefrontal Transcranial Magnetic Stimulation in Episodic Migraine Prophylaxis	N/A
Completed	`NCT05264129` - Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine	Phase 4
Completed	`NCT04740827` - Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.	Phase 3
Completed	`NCT05853900` - Study of Two Digital Therapeutics for the Prevention of Episodic Migraine	Phase 3

NCT number	NCT03700320
Study type	Interventional
Source	Allergan
Contact
Status	Completed
Phase	Phase 3
Start date	October 8, 2018
Completion date	May 21, 2020

Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms